1. AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. Issue 10296 (17th July 2021) Authors: Wall, Emma C; Wu, Mary; Harvey, Ruth; Kelly, Gavin; Warchal, Scott; Sawyer, Chelsea; Daniels, Rodney; Adams, Lorin; Hobson, Philip; Hatipoglu, Emine; Ngai, Yenting; Hussain, Saira; Ambrose, Karen; Hindmarsh, Steve; Beale, Rupert; Riddell, Andrew; Gamblin, Steve; Howell, Michael; Kassiotis, George... Journal: Lancet Issue: Volume 398:Issue 10296(2021) Page Start: 207 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795–813, 5511]. Issue 5 (May 2023) Authors: Liu, Xinxue; Munro, Alasdair PS; Feng, Shuo; Janani, Leila; Aley, Parvinder K; Babbage, Gavin; Baxter, David; Bula, Marcin; Cathie, Katrina; Chatterjee, Krishna; Dejnirattisai, Wanwisa; Dodd, Kate; Enever, Yvanne; Qureshi, Ehsaan; Goodman, Anna L.; Green, Christopher A; Harndahl, Linda; Haughney,... Journal: Journal of infection Issue: Volume 86:Issue 5(2023) Page Start: 540 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2. (February 2023) Authors: Szubert, Alex J.; Pollock, Katrina M.; Cheeseman, Hannah M.; Alagaratnam, Jasmini; Bern, Henry; Bird, Olivia; Boffito, Marta; Byrne, Ruth; Cole, Tom; Cosgrove, Catherine A.; Faust, Saul N.; Fidler, Sarah; Galiza, Eva; Hassanin, Hana; Kalyan, Mohini; Libri, Vincenzo; McFarlane, Leon R.; Milinkovic... Journal: EClinicalMedicine Issue: Volume 56(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Determination of [11C]PBR28 Binding Potential in vivo: A First Human TSPO Blocking Study. Issue 6 (June 2014) Authors: Owen, David R; Guo, Qi; Kalk, Nicola J; Colasanti, Alessandro; Kalogiannopoulou, Dimitra; Dimber, Rahul; Lewis, Yvonne L; Libri, Vincenzo; Barletta, Julien; Ramada-Magalhaes, Joaquim; Kamalakaran, Aruloly; Nutt, David J; Passchier, Jan; Matthews, Paul M; Gunn, Roger N; Rabiner, Eugenii A Journal: Journal of cerebral blood flow & metabolism Issue: Volume 34:Issue 6(2014) Page Start: 989 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Determination of [11C]PBR28 Binding Potential in vivo: A First Human TSPO Blocking Study. Issue 7 (July 2014) Authors: Owen, David R; Guo, Qi; Kalk, Nicola J; Colasanti, Alessandro; Kalogiannopoulou, Dimitra; Dimber, Rahul; Lewis, Yvonne L; Libri, Vincenzo; Barletta, Julien; Ramada-Magalhaes, Joaquim; Kamalakaran, Aruloly; Nutt, David J; Passchier, Jan; Matthews, Paul M; Gunn, Roger N; Rabiner, Eugenii A Journal: Journal of cerebral blood flow & metabolism Issue: Volume 34:Issue 7(2014) Page Start: 1256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. Issue 11 (November 2022) Authors: Shaw, Robert H; Liu, Xinxue; Stuart, Arabella S V; Greenland, Melanie; Aley, Parvinder K; Andrews, Nick J; Cameron, J Claire; Charlton, Sue; Clutterbuck, Elizabeth A; Collins, Andrea M; Dejnirattisai, Wanwisa; Dinesh, Tanya; Faust, Saul N; Ferreira, Daniela M; Finn, Adam; Green, Christopher A; Ha... Journal: Lancet Issue: Volume 10:Issue 11(2022) Page Start: 1049 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Issue 10282 (10th April 2021) Authors: Emary, Katherine R W; Golubchik, Tanya; Aley, Parvinder K; Ariani, Cristina V; Angus, Brian; Bibi, Sagida; Blane, Beth; Bonsall, David; Cicconi, Paola; Charlton, Sue; Clutterbuck, Elizabeth A; Collins, Andrea M; Cox, Tony; Darton, Thomas C; Dold, Christina; Douglas, Alexander D; Duncan, Christoph... Journal: Lancet Issue: Volume 397:Issue 10282(2021) Page Start: 1351 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study. Issue 5 (28th May 2021) Authors: Vijiaratnam, Nirosen; Girges, Christine; Auld, Grace; Chau, Marisa; Maclagan, Kate; King, Alexa; Skene, Simon; Chowdhury, Kashfia; Hibbert, Steve; Morris, Huw; Limousin, Patricia; Athauda, Dilan; Carroll, Camille B; Hu, Michele T; Silverdale, Monty; Duncan, Gordon W; Chaudhuri, Ray; Lo, Christine... Journal: BMJ open Issue: Volume 11:Issue 5(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Issue 10319 (1st January 2022) Authors: Stuart, Arabella S V; Shaw, Robert H; Liu, Xinxue; Greenland, Melanie; Aley, Parvinder K; Andrews, Nick J; Cameron, J C; Charlton, Sue; Clutterbuck, Elizabeth A; Collins, Andrea M; Darton, Tom; Dinesh, Tanya; Duncan, Christopher J A; England, Anna; Faust, Saul N; Ferreira, Daniela M; Finn, Adam; ... Journal: Lancet Issue: Volume 399:Issue 10319(2022) Page Start: 36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. Issue 3 (March 2022) Authors: Fisher, Benjamin A; Veenith, Tonny; Slade, Daniel; Gaskell, Charlotte; Rowland, Matthew; Whitehouse, Tony; Scriven, James; Parekh, Dhruv; Balasubramaniam, Madhu S; Cooke, Graham; Morley, Nick; Gabriel, Zoe; Wise, Matthew P; Porter, Joanna; McShane, Helen; Ho, Ling-Pei; Newsome, Philip N; Rowe, An... Journal: Lancet Issue: Volume 10:Issue 3(2022) Page Start: 255 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗